Core Insights - The company’s subsidiary, Seacross Pharma Ltd., has recently obtained marketing approvals from the German Federal Institute for Drugs and Medical Devices and the Saudi Food and Drug Authority for several products, including Zoledronic Acid Injection, Injection for Cetuximab, Sodium Valproate Injection Concentrate, and Bendamustine Hydrochloride Injection [1] Group 1 - The approvals will help the company enhance its international product pipeline, improve brand image, and expand the breadth and depth of its international business [1] - The company has prepared for the market launch and sales of these products [1] - Future revenue generation remains uncertain due to market competition and other factors [1]